###begin article-title 0
###xml 28 32 <span type="species:ncbi:10090">mice</span>
Accelerated tumor growth in mice deficient in DNAM-1 receptor
###end article-title 0
###begin p 1
###xml 30 55 30 55 <email xmlns:xlink="http://www.w3.org/1999/xlink">ashibuya@md.tsukuba.ac.jp</email>
###xml 75 99 75 99 <email xmlns:xlink="http://www.w3.org/1999/xlink">kazukos@md.tsukuba.ac.jp</email>
CORRESPONDENCE Akira Shibuya: ashibuya@md.tsukuba.ac.jp OR Kazuko Shibuya: kazukos@md.tsukuba.ac.jp
###end p 1
###begin p 2
This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see ). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at ).
###end p 2
###begin p 3
###xml 40 45 <span type="species:ncbi:9606">human</span>
###xml 50 55 <span type="species:ncbi:10090">mouse</span>
###xml 374 378 <span type="species:ncbi:10090">mice</span>
###xml 683 687 <span type="species:ncbi:10090">mice</span>
###xml 807 811 <span type="species:ncbi:10090">mice</span>
###xml 1012 1016 <span type="species:ncbi:10090">mice</span>
Since the identification of ligands for human and mouse DNAM-1, emerging evidence has suggested that DNAM-1 plays an important role in the T cell- and natural killer (NK) cell-mediated recognition and lysis of tumor cells. However, it remains undetermined whether DNAM-1 is involved in tumor immune surveillance in vivo. We addressed this question by using DNAM-1-deficient mice. DNAM-1-deficient cytotoxic T lymphocyte (CTL) and NK cells showed significantly less cytotoxic activity against DNAM-1 ligand-expressing tumors in vitro than wild-type (WT) cells. The methylcholanthrene (MCA)-induced fibrosarcoma cell line Meth A expressed the DNAM-1 ligand CD155, and DNAM-1-deficient mice showed increased tumor development and mortality after transplantation of Meth A cells. Moreover, the DNAM-1-deficient mice developed significantly more DNAM-1 ligand-expressing fibrosarcoma and papilloma cells in response to the chemical carcinogens MCA and 7,12-dimethylbenz[a]anthracene (DMBA), respectively, than did WT mice. These results indicate that DNAM-1 plays an important role in immune surveillance of tumor development.
###end p 3
###begin p 4
A. Iguchi-Manaka and H. Kai contributed equally to this paper.
###end p 4
###begin p 5
###xml 178 179 178 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 181 182 181 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 519 520 519 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 522 523 522 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 683 684 683 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
Several lines of evidence demonstrate that the immune system protects the host against tumor development. CTL and NK cells are major players in cell-mediated immunity to tumors (1, 2). Tumor recognition by and activation of CTL and NK cells are mediated by antigen receptors and a variety of adhesion and costimulatory molecules including CD2, LFA-1 (leukocyte function-associated antigen-1; CD11a/CD18), CD27, 2B4, CD28, ICOS (inducible costimulator), NKG2D, TRAIL (TNF-related apoptosis-inducing ligand), and others (2, 3). Interactions of these cell surface receptors with their respective ligands expressed on tumors induce cytotoxic activity of CTL and NK cells against tumors (4).
###end p 5
###begin p 6
###xml 142 143 142 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 144 145 144 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 205 206 205 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 398 399 398 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 572 573 572 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 686 687 686 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 847 849 847 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 850 852 850 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 1014 1016 1014 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 1018 1020 1018 1020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 1131 1133 1131 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 1135 1137 1135 1137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 1256 1258 1256 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 1260 1262 1260 1262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 1282 1284 1282 1284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 1304 1306 1304 1306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 1325 1327 1325 1327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 1349 1351 1349 1351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 1376 1378 1376 1378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 1638 1643 1638 1643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cd226</italic>
###xml 1645 1651 1645 1651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DNAM-1</italic>
###xml 694 704 <span type="species:ncbi:138953">poliovirus</span>
###xml 823 828 <span type="species:ncbi:9606">human</span>
###xml 833 838 <span type="species:ncbi:10090">mouse</span>
###xml 1032 1037 <span type="species:ncbi:9606">human</span>
###xml 1621 1625 <span type="species:ncbi:10090">mice</span>
DNAM-1 (CD226) is a member of the immunoglobulin superfamily and is expressed on the majority of NK cells, T cells, monocytes, and platelets (5-7). DNAM-1 constitutively associates with LFA-1 on NK cells (8). Ligation of LFA-1 with antibodies causes Fyn-dependent phosphorylation of tyrosine residues in the cytoplasmic domain of DNAM-1, which are necessary for DNAM-1-dependent NK cell functions (8). DNAM-1 also associates with LFA-1 in activated T cells, for which the protein kinase C-induced serine phosphorylation in the cytoplasmic domain of DNAM-1 is responsible (8), and is involved in an LFA-1-mediated costimulatory signal for naive T cell differentiation and proliferation (9). The poliovirus receptor (PVR) CD155 and its family member CD112 (PRR-2 [PVR-related family 2], also called nectin-2) are ligands for human and mouse DNAM-1 (10-12). Interactions between DNAM-1 on NK cells and T cells and its ligands CD112 and CD155 on tumor cells augment cell-mediated cytotoxicity and cytokine production (10, 11). Although human CD112 and CD155 are broadly distributed on epithelial and endothelial cells in many tissues (13, 14), they are overexpressed on certain tumors, both nonhematopoietic and hematopoietic, including colorectal carcinomas (15, 16), gastric cancers (16), ovarian cancers (17), neuroblastomas (18), myeloid leukemias (19), and multiple myeloma (20), suggesting that DNAM-1 ligand expression might be induced by tumorigenesis and, thus, stimulates CTL and NK cells. However, it remains uncertain whether DNAM-1 is involved in immune surveillance of tumors in vivo. We therefore generated KO mice lacking the Cd226 (DNAM-1) gene and investigated the in vivo role of DNAM-1 in tumor immunity.
###end p 6
###begin title 7
RESULTS AND DISCUSSION
###end title 7
###begin title 8
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse DNAM-1 mediates cytotoxic activity of CTL and NK cells
###end title 8
###begin p 9
###xml 215 216 215 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 218 220 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">10</xref>
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 460 465 460 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cd226</italic>
###xml 467 473 467 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DNAM-1</italic>
###xml 506 512 506 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DNAM-1</italic>
###xml 717 722 717 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cd226</italic>
###xml 867 868 867 868 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 885 886 885 886 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 904 905 904 905 <sup xmlns:xlink="http://www.w3.org/1999/xlink">k</sup>
###xml 964 972 964 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
###xml 1107 1115 1107 1115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
###xml 1214 1215 1214 1215 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 1244 1245 1244 1245 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1268 1269 1268 1269 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1340 1348 1340 1348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
###xml 1375 1376 1375 1376 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1583 1584 1583 1584 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1720 1721 1720 1721 <sup xmlns:xlink="http://www.w3.org/1999/xlink">k</sup>
###xml 1770 1771 1770 1771 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1782 1790 1782 1790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 1907 1915 1907 1915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 51 56 <span type="species:ncbi:9606">human</span>
###xml 243 248 <span type="species:ncbi:9606">human</span>
###xml 357 362 <span type="species:ncbi:10090">mouse</span>
###xml 443 447 <span type="species:ncbi:10090">mice</span>
###xml 516 520 <span type="species:ncbi:10090">mice</span>
###xml 570 574 <span type="species:ncbi:10090">mice</span>
###xml 835 840 <span type="species:ncbi:10090">mouse</span>
###xml 1205 1209 <span type="species:ncbi:10090">mice</span>
###xml 1211 1215 <span type="species:ncbi:10090">H-2d</span>
Previous studies demonstrated that the addition of human DNAM-1-neutralizing antibodies to in vitro cytotoxicity assays inhibited CTL or NK cell-mediated lysis of several tumor cell lines expressing DNAM-1 ligands (5, 10, 11), suggesting that human DNAM-1 is involved in CTL and NK cell-mediated cytotoxicity. However, the role of DNAM-1 in cytotoxicity of mouse CTL and NK cells has not been investigated. To address this issue, we generated mice lacking the Cd226 (DNAM-1) gene in the BALB/c background (DNAM-1 KO mice; Fig. S1, available at ). Naive DNAM-1-deficient mice showed a normal composition of lymphocyte populations in the spleen, BM, and LN (Fig. S2 and not depicted), suggesting that the disruption of Cd226 did not affect lymphocyte differentiation. We then examined the expression of DNAM-1 ligands CD155 and CD112 in mouse tumor cell lines EL-4 (H-2b), RL male-1 (H-2d), and BW5147 (H-2k). These cell lines expressed comparable amounts of CD155 (Fig. 1 A). In contrast, CD112 was expressed on RMA transfectant expressing CD112 (RMA-CD112) but was barely detected on the other tumor cells (Fig. 1 A). We next generated CTL by coculture of spleen cells from WT and DNAM-1-deficient BALB/c mice (H-2d) with the RMA cell line (H-2b) and then purified CD8+ T cells by sorting. Because RMA cells did not express DNAM-1 ligands (Fig. 1 A) and the population of CD8+ T cells after the culture was comparable between WT and KO spleen cells (not depicted), DNAM-1 deficiency did not affect the induction of DNAM-1-deficient CTL cells. The purified WT and DNAM-1-deficient CD8+ T cells specifically killed EL-4 tumor cells as well as RMA transfectant expressing CD115 (RMA-CD155), but not RL male-1 or BW5147 (H-2k) target cells, suggesting that both CTL were H-2b specific (Fig. 1 B). However, DNAM-1-deficient CTL were significantly less cytotoxic to RMA-CD155 and EL-4 than were the WT CTL cells (Fig. 1 B).
###end p 9
###begin p 10
###xml 0 111 0 111 <bold xmlns:xlink="http://www.w3.org/1999/xlink">DNAM-1 is involved in NK cell&#8211; and CTL-mediated cytotoxicity against DNAM-1 ligand&#8211;expressing tumor cell lines.</bold>
###xml 253 254 253 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 267 268 267 268 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 283 284 283 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 342 343 342 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 366 368 366 368 <sup xmlns:xlink="http://www.w3.org/1999/xlink">51</sup>
###xml 451 453 451 453 <sup xmlns:xlink="http://www.w3.org/1999/xlink">51</sup>
###xml 487 488 487 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 515 516 515 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 333 337 <span type="species:ncbi:10090">mice</span>
###xml 339 343 <span type="species:ncbi:10090">H-2d</span>
###xml 522 526 <span type="species:ncbi:10090">mice</span>
DNAM-1 is involved in NK cell- and CTL-mediated cytotoxicity against DNAM-1 ligand-expressing tumor cell lines. (A) Tumor cell lines or transfectants indicated were stained with anti-CD155 or anti-CD112 mAbs and analyzed by flow cytometry. (B and C) H-2b-specific CD8+ CTL (B) or DX5+ NK (C) cells from WT or DNAM-1-deficient BALB/c mice (H-2d) were cocultured with 51Cr-labeled target cells indicated for 3 h. Culture supernatants were harvested and 51Cr releases were counted. (D) WT (n = 5) or DNAM-1-deficient (n = 5) mice were injected i.p. with a 1:1 mixture of CFSE-labeled RMA-S and RMA-S-CD155. 12 h after injection, cells were harvested from the peritoneal cavities and analyzed for the ratio of RMA-S-CD155 to RMA-S cells by flow cytometry. Data are representative of three independent experiments. Error bars show SD.
###end p 10
###begin p 11
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 306 321 306 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, A and C</xref>
We also examined the cytotoxicity of DNAM-1-deficient NK cells. These cells showed no defect in cytolysis of Yac-1 tumor cells (Fig. S3, available at ), which substantially express NKG2D ligands (21) but not DNAM-1 ligands. However, they showed less cytotoxicity to RMA-S-CD155 cells than did WT NK cells (Fig. 1, A and C). These results together formally demonstrate that DNAM-1 is involved in both CTL and NK cell-mediated cytotoxicity.
###end p 11
###begin title 12
###xml 17 21 <span type="species:ncbi:10090">mice</span>
DNAM-1-deficient mice showed impaired clearance of CD155-expressing tumor cells
###end title 12
###begin p 13
###xml 418 426 418 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 D</xref>
###xml 91 95 <span type="species:ncbi:10090">mice</span>
###xml 380 384 <span type="species:ncbi:10090">mice</span>
###xml 412 416 <span type="species:ncbi:10090">mice</span>
We next investigated the role of DNAM-1 in tumor clearance in vivo. WT or DNAM-1-deficient mice were injected i.p. with a 1:1 mixture of CFSE-labeled RMA-S and RMA-S-CD155 cells. At 12 h, tumor cells were harvested from the peritoneal cavity and analyzed for the ratio of cell numbers by flow cytometry. We recovered significantly fewer RMA-S-CD155 cells than RMA-S cells from WT mice than from DNAM-1-deficient mice (Fig. 1 D). Considering the short time interval, NK cells, rather than CTL, might be involved in the clearance of RMA-S-CD155 cells. These results suggest that DNAM-1 plays an important role in the clearance of tumors expressing CD155 in vivo.
###end p 13
###begin title 14
###xml 17 21 <span type="species:ncbi:10090">mice</span>
DNAM-1-deficient mice showed higher mortality after transplantation of Meth A cells
###end title 14
###begin p 15
###xml 130 131 130 131 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 428 436 428 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 466 467 466 467 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 590 598 590 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 637 638 637 638 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 834 842 834 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 C</xref>
###xml 75 79 <span type="species:ncbi:10090">mice</span>
###xml 422 426 <span type="species:ncbi:10090">mice</span>
###xml 490 494 <span type="species:ncbi:10090">mice</span>
###xml 667 671 <span type="species:ncbi:10090">mice</span>
###xml 735 739 <span type="species:ncbi:10090">mice</span>
###xml 804 808 <span type="species:ncbi:10090">mice</span>
We previously demonstrated that although RMA tumor cells grew in syngeneic mice, RMA-CD155 or RMA-CD112 cells were rejected by CD8+ T cells and NK cells, suggesting that DNAM-1 was involved in the rejection (16). To provide formal evidence for the role of DNAM-1 in protecting against DNAM-1 ligand-expressing tumors in vivo, we transplanted Meth A tumors that expressed CD155, but not CD112, into WT and DNAM-1-deficient mice (Fig. 2 A). When inoculated with 2 x 105 cells, both groups of mice developed tumors by 3-4 wk after inoculation, and their survival and mortality did not differ (Fig. 2 B). However, when inoculated with 2 x 104 cells, all DNAM-1-deficient mice developed tumors by 20 d after inoculation, but 6 out of 10 WT mice showed no evidence of tumor development and the mortality of WT mice was significantly lower (Fig. 2 C). These results indicate that DNAM-1 was involved in the rejection of the Meth A tumors.
###end p 15
###begin p 16
###xml 0 46 0 46 <bold xmlns:xlink="http://www.w3.org/1999/xlink">DNAM-1 is involved in tumor rejection in vivo.</bold>
###xml 161 162 161 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 171 172 171 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 203 204 203 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 213 214 213 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 258 259 258 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 273 274 273 274 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 221 225 <span type="species:ncbi:10090">mice</span>
###xml 315 320 <span type="species:ncbi:10090">mouse</span>
DNAM-1 is involved in tumor rejection in vivo. (A) Meth A cells were stained with anti-CD155 or anti-CD112 mAbs and analyzed by flow cytometry. (B and C) WT (B, n = 5; C, n = 10) or DNAM-1-deficient (B, n = 5; C, n = 10) mice were inoculated s.c. with 2 x 104 (B) or 2 x 105 (C) Meth A on day 0. Tumor size in each mouse was measured three times a week. Survival data per group are shown. The experiments were performed twice with similar results. One experiment is shown.
###end p 16
###begin title 17
DNAM-1 deficiency enhanced the development of 3-methylcholanthrene (MCA)-induced fibrosarcoma
###end title 17
###begin p 18
###xml 333 341 331 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 509 517 506 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 191 195 <span type="species:ncbi:10090">mice</span>
###xml 270 274 <span type="species:ncbi:10090">mice</span>
###xml 413 417 <span type="species:ncbi:10090">mice</span>
###xml 503 507 <span type="species:ncbi:10090">mice</span>
Because Meth A is an MCA-induced fibrosarcoma cell line, we examined whether DNAM-1 might also be involved in immune surveillance of fibrosarcoma after MCA injection. WT and DNAM-1-deficient mice were injected s.c. with 25 or 400 mug MCA. At 400 mug MCA, both groups of mice similarly developed fibrosarcoma by 30 d after injection (Fig. 3 A) and showed no difference in mortality. In contrast, at 25 mug MCA, WT mice developed tumors more slowly and survived significantly longer than DNAM-1-deficient mice (Fig. 3 A). These results suggest that DNAM-1 played an important role in immune surveillance of MCA-induced fibrosarcoma.
###end p 18
###begin p 19
###xml 0 75 0 75 <bold xmlns:xlink="http://www.w3.org/1999/xlink">DNAM-1 is involved in immune surveillance against MCA-induced fibrosarcoma.</bold>
###xml 84 85 84 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 113 114 113 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 503 508 500 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD155</italic>
###xml 513 518 510 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD112</italic>
###xml 121 125 <span type="species:ncbi:10090">mice</span>
###xml 201 206 <span type="species:ncbi:10090">mouse</span>
###xml 274 278 <span type="species:ncbi:10090">mice</span>
###xml 379 383 <span type="species:ncbi:10090">mice</span>
###xml 456 461 <span type="species:ncbi:10090">mouse</span>
###xml 555 559 <span type="species:ncbi:10090">mice</span>
DNAM-1 is involved in immune surveillance against MCA-induced fibrosarcoma. (A) WT (n = 10) or DNAM-1-deficient (n = 10) mice were injected s.c. with 400 mug or 25 mug MCA on day 0. Tumor size in each mouse was measured once a week. Tumor incidence and survival data for 10 mice per group are shown. (B) When 25 mug MCA-induced fibrosarcomas in seven WT or nine DNAM-1-deficient mice reached a size of 1 cm in diameter, fibrosarcoma was resected from each mouse and subjected to quantitative RT-PCR for CD155 and CD112. The skins resected from four naive mice were also subjected to quantitative RT-PCR. The data are the mean of triplicates. The experiments were performed twice with similar results. One experiment is shown.
###end p 19
###begin p 20
###xml 270 275 269 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD155</italic>
###xml 280 285 279 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD112</italic>
###xml 442 450 441 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 B</xref>
###xml 526 531 525 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD112</italic>
###xml 553 558 552 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD155</italic>
###xml 630 638 629 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 B</xref>
###xml 976 978 975 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 1218 1220 1217 1219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 255 259 <span type="species:ncbi:10090">mice</span>
###xml 436 440 <span type="species:ncbi:10090">mice</span>
###xml 624 628 <span type="species:ncbi:10090">mice</span>
To further assess the role of DNAM-1 in immune surveillance of MCA-induced fibrosarcoma, we used quantitative RT-PCR to evaluate DNAM-1 ligand expression on fibrosarcoma cells that were developed after injection of 25 mug MCA into WT and DNAM-1-deficient mice. Although CD155 and CD112 messenger RNAs (mRNAs) were barely detected in naive derma, MCA-induced fibrosarcoma cells expressed significant quantities of both in both groups of mice (Fig. 3 B). Notably, although the fibrosarcoma cells expressed comparable amounts of CD112 mRNA in both groups, CD155 mRNA expression was significantly higher in the DNAM-1-deficient mice (Fig. 3 B). These results suggest that DNAM-1 recognition of CD155 on fibrosarcoma cells was involved in tumor immune surveillance, which is consistent with the "immunoediting" theory in which immune responses select for variant tumor cells which have lost or decreased expression of specific molecules that are targeted by immune effector cells (22). In contrast to CD155, CD112 seemed not to be involved in immunoediting. This may be explained by our previous observations that the affinities of homotypic binding of CD112 were likely to be higher than those of CD112 binding to DNAM-1 (12).
###end p 20
###begin p 21
###xml 213 214 213 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 277 279 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 302 304 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 306 308 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 321 323 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 325 327 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 345 347 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 348 350 333 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 490 495 475 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRAIL</italic>
###xml 497 499 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
###xml 557 559 542 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 943 949 928 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 1006 1008 991 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 217 221 <span type="species:ncbi:10090">Mice</span>
###xml 472 476 <span type="species:ncbi:10090">mice</span>
Recent studies using genetically engineered animals have demonstrated that a variety of immune cells in both the innate and adaptive immune systems are involved in tumor immunoediting of MCA-induced fibrosarcoma (4). Mice lacking cellular components such as alphabeta T cells (23), gammadelta T cells (23, 24), NK cells (25, 26), or NK T cells (25-27) developed higher rates of MCA-induced fibrosarcoma. The development of fibrosarcoma induced by MCA was also enhanced in mice deficient in TRAIL (28) or injected with a neutralizing antibody against TRAIL (29), which is constitutively expressed on liver NK cells and might be involved in NK cell-mediated immunity to fibrosarcoma development. However, activating receptors constitutively expressed on T cells and NK cells in the spleen have not yet been identified. In the present and previous studies, we showed that DNAM-1 was involved in CTL and NK cell-mediated tumor cytolysis in vitro (Fig. 1) and in the rejection of transplanted tumor cell lines (29), suggesting that DNAM-1 was responsible for CTL and/or NK cell-mediated immune surveillance of fibrosarcoma development induced by MCA.
###end p 21
###begin title 22
DNAM-1 deficiency enhanced the development of 7,12-dimethylbenz[a]anthracene (DMBA)-induced papilloma
###end title 22
###begin p 23
###xml 334 335 333 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 369 375 368 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4</xref>
###xml 558 564 557 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4</xref>
###xml 664 670 663 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4</xref>
###xml 791 796 790 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD155</italic>
###xml 801 806 800 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD112</italic>
###xml 143 147 <span type="species:ncbi:10090">mice</span>
###xml 234 238 <span type="species:ncbi:10090">mice</span>
###xml 409 413 <span type="species:ncbi:10090">mice</span>
###xml 474 478 <span type="species:ncbi:10090">mice</span>
###xml 530 535 <span type="species:ncbi:10090">mouse</span>
###xml 617 621 <span type="species:ncbi:10090">mice</span>
###xml 658 662 <span type="species:ncbi:10090">mice</span>
###xml 949 953 <span type="species:ncbi:10090">mice</span>
###xml 1034 1039 <span type="species:ncbi:10090">mouse</span>
To examine whether DNAM-1 is involved in immune surveillance of tumors other than MCA-induced fibrosarcoma, we treated WT and DNAM-1-deficient mice with DMBA, a chemical carcinogen that induces papillomas on the skin. One out of five mice in each group developed papillomas by 80 d after treatment with 400 mug DMBA alone, without 12-O-tetradecanoylphorbol 13-acetate (Fig. 4). The number of DNAM-1-deficient mice with papillomas increased by 100 d and all DNAM-1-deficient mice developed papillomas by 150 d, yet only the one WT mouse developed papillomas (Fig. 4). The mean number of papillomas in DNAM-1-deficient mice was significantly higher than in WT mice (Fig. 4). To further assess the role of DNAM-1 in immune surveillance of DMBA-induced papillomas, we examined the expression of CD155 and CD112 mRNAs in the papillomas by quantitative RT-PCR. We detected both in significant amounts in all eight papillomas developed in DNAM-1-deficient mice (unpublished data). We also detected both in two papillomas developed in the WT mouse, but we could not statistically compare the expressions between groups. Nonetheless, these results indicate that DNAM-1 plays an important role in immune surveillance of DMBA-induced papilloma as well as that of MCA-induced fibrosarcoma.
###end p 23
###begin p 24
###xml 0 73 0 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink">DNAM-1 is involved in immune surveillance against DMBA-induced papilloma.</bold>
###xml 78 79 78 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 106 107 106 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 113 117 <span type="species:ncbi:10090">mice</span>
###xml 202 207 <span type="species:ncbi:10090">mouse</span>
DNAM-1 is involved in immune surveillance against DMBA-induced papilloma. WT (n = 5) or DNAM-1-deficient (n = 5) mice were treated with 400 mug DMBA on day 0. The number of papillomas developed in each mouse was observed twice a week. The mean number of papillomas and tumor incidence per group are shown. The experiments were performed twice with similar results. One experiment is shown.
###end p 24
###begin p 25
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 209 213 <span type="species:ncbi:10090">mice</span>
Emerging evidence suggests that DNAM-1 plays an important role in T cell- and NK cell-mediated immunity to a variety of tumors expressing DNAM-1 ligands (15-20). This is the first study using DNAM-1-deficient mice to demonstrate direct genetic evidence for a role of the DNAM-1 receptor in immune surveillance of chemical carcinogen-induced tumors. Future studies aimed at the clinical application of DNAM-1 as a potential molecular target for the treatment of cancer should be interesting.
###end p 25
###begin title 26
MATERIALS AND METHODS
###end title 26
###begin title 27
###xml 24 28 <span type="species:ncbi:10090">mice</span>
Generation of DNAM-1 KO mice.
###end title 27
###begin p 28
###xml 70 75 70 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cd226</italic>
###xml 77 83 77 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DNAM-1</italic>
###xml 180 182 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 476 481 476 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cd226</italic>
###xml 481 484 481 484 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 487 492 487 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cd226</italic>
###xml 492 495 492 495 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 531 536 531 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cd226</italic>
###xml 536 539 536 539 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 638 643 638 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cd226</italic>
###xml 643 646 643 646 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 470 474 <span type="species:ncbi:10090">mice</span>
###xml 496 500 <span type="species:ncbi:10090">mice</span>
###xml 540 544 <span type="species:ncbi:10090">mice</span>
###xml 557 561 <span type="species:ncbi:10090">mice</span>
###xml 647 651 <span type="species:ncbi:10090">mice</span>
###xml 667 671 <span type="species:ncbi:10090">mice</span>
To construct the DNAM-1 targeting vector, we replaced exon 2-3 of the Cd226 (DNAM-1) gene with a neomycin-resistant gene cassette using the bacterial artificial chromosome system (30). BALB/c embryonic stem cells were electroporated with the linearized DNAM-1 targeting vector, and cells were selected for G418 antibiotic resistance. Correctly targeted embryonic stem cell clones with normal karyotypes were injected into 3.5-d-old BALB/c blastocysts to create chimeric mice (Cd226+/-). Cd226+/- mice were intercrossed to generate cd226-/- mice. Homozygous mice were obtained at the expected Mendelian frequencies and developed normally. Cd226-/- mice and control WT mice were bred under specific pathogen-free conditions in the same room of our animal facility. All experiments were performed according to the guidelines of the animal ethics committee of the University of Tsukuba Animal Research Center.
###end p 28
###begin title 29
Cell lines and antibodies.
###end title 29
###begin p 30
###xml 14 16 14 16 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 26 28 26 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b+</sup>
###xml 94 96 94 96 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d+</sup>
###xml 180 182 180 182 <sup xmlns:xlink="http://www.w3.org/1999/xlink">k+</sup>
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 91 95 <span type="species:ncbi:10090">H-2d</span>
RMA and EL-4 (31) were H-2b+ T lymphoma cell lines. Meth A, RL male-1, A20, and SP2/0 were H-2d+ fibroblast, T cell, B cell, and myeloma cell lines, respectively. BW5147 was an H-2k+ T lymphoma cell line. Anti-CD8 and -DX5 monoclonal antibodies were purchased from BD. Anti-DNAM-1 (TX42) (16), anti-CD155 (TX56), and anti-CD112 (TX78) antibodies were generated in our laboratory.
###end p 30
###begin title 31
Generation of CTL and NK cells.
###end title 31
###begin p 32
###xml 20 21 20 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 42 43 42 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 148 149 147 148 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 200 201 199 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 374 375 373 374 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 383 384 382 383 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
We cocultured 5 x 106 spleen cells with 106 RMA cells, pretreated with 100 mug/ml mitomycin C, in a 24-well plate for 5 d and then with purified CD8+ T cells by using the IMAG sorting system (BD). DX5+ cells were purified from the spleen by using magnetic activated cell sorting (MACS; Miltenyi Biotec) and cultured in the presence of 200 ng/ml IL-2 for 5 d. Purities of CD8+ and DX5+ cells were >95%, as determined by flow cytometry.
###end p 32
###begin title 33
Cytotoxicity assay.
###end title 33
###begin p 34
###xml 60 62 60 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
Cytotoxicity assays were performed as described previously (11).
###end p 34
###begin title 35
Tumor clearance assay.
###end title 35
###begin p 36
###xml 113 114 113 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 23 27 <span type="species:ncbi:10090">mice</span>
WT or DNAM-1-deficient mice were injected i.p. with a 1:1 mixture of CFSE-labeled RMA-S and RMA-S-CD155 cells (106 each). 12 h after injection, tumor cells were harvested from the peritoneal cavities and analyzed by flow cytometry.
###end p 36
###begin title 37
###xml 35 39 <span type="species:ncbi:10090">mice</span>
Tumor growth assay and survival of mice.
###end title 37
###begin p 38
###xml 379 381 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 46 50 <span type="species:ncbi:10090">mice</span>
###xml 179 184 <span type="species:ncbi:4577|species:ncbi:381124">maize</span>
###xml 270 274 <span type="species:ncbi:10090">Mice</span>
Groups of 5 or 10 WT or DNAM-1-deficient male mice were injected s.c. in the back with transplantable tumor cell lines, with 25 or 400 mug MCA (Sigma-Aldrich) dissolved in 0.1 ml maize oil, or were painted with 400 mug DMBA (Sigma-Aldrich) dissolved in 4 mM of acetone. Mice were examined once or three times a week for tumor size with a caliper square, as previously described (16).
###end p 38
###begin title 39
Quantitative RT-PCR.
###end title 39
###begin p 40
###xml 257 262 255 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD155</italic>
###xml 267 273 265 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD112d</italic>
###xml 430 435 428 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD155</italic>
###xml 517 523 515 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD112d</italic>
###xml 605 610 603 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 1021 1026 1001 1006 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD155</italic>
###xml 1052 1058 1032 1038 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD112d</italic>
Total RNA was extracted from fibrosarcomas and naive derma with Isogen reagent (Nippon Gene). For RT, we used 2-5 mug of total RNA in a High-Capacity cDNA Reverse Transcription kit (Applied Biosystems) at a final volume of 20 mul. Real-time PCR analysis of CD155 and CD112d was performed with an ABI 7700 sequence detector (Applied Biosystems) with Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen). The primers were as follows: CD155 forward, 5'-CAACTGGTATGTTGGCCTCA-3' and reverse, 5'-ATTGGTGACTTCGCACACAA-3'; and CD112d forward, 5'-CTCTGTGGATCGAATGGTCA-3' and reverse, 5'-GGCAGCGATAATACCTCCAA-3'. The GAPDH level was measured as an internal control (upper primer, 5'-CTTCACCACCATGGAGAAGGC-3'; and lower primer, 5'-GGCATGGACTGTGGTCATGAG-3') to normalize the data. The thermal cycling conditions comprised an initial denaturation step at 95degreesC for 10 min, followed by 40 cycles at 95degreesC for 15 s and 60degreesC for 1 min. Standard curves were generated by using serial dilutions of cDNA from Meth A cells for CD155 and BaF-CD112d cells for CD112d. All values were determined in triplicate.
###end p 40
###begin title 41
Statistics.
###end title 41
###begin p 42
###xml 68 69 68 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
Statistical analyses were performed by using the unpaired Student's t test.
###end p 42
###begin title 43
Online supplemental material.
###end title 43
###begin p 44
###xml 64 69 64 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cd226</italic>
###xml 108 113 108 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cd226</italic>
###xml 408 409 408 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 437 438 437 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 542 544 542 544 <sup xmlns:xlink="http://www.w3.org/1999/xlink">51</sup>
###xml 313 317 <span type="species:ncbi:10090">mice</span>
###xml 444 448 <span type="species:ncbi:10090">mice</span>
Fig. S1 shows the construct of DNAM-1 targeting vector, genomic Cd226 analyzed by RT-PCR, the expression of Cd226 mRNA in the tail, and DNAM-1 protein on the spleen cells by staining with FITC-conjugated anti-CD8 and biotin-conjugated anti-DNAM-1 (TX42), followed with PE-conjugated streptavidin in the indicated mice. Fig. S2 shows the lymphocytes population in the thymus and spleen cells derived from WT (n = 5) and DNAM-1-deficient (n = 5) mice. Fig. S3 show the cytotoxicities of Yac-1 by WT and DNM-1-deficient NK cells, as analyzed by 51Cr releases assay. Online supplemental material is available at .
###end p 44
###begin title 45
Supplementary Material
###end title 45
###begin title 46
[Supplemental Material Index]
###end title 46
###begin p 47
We thank Lewis Lanier (University of California, San Francisco) for critical reading of the manuscript, Eiichi Nakayama (Okayama University) for discussion, and Yurika Soeda for secretarial assistance.
###end p 47
###begin p 48
This research was supported in part by grants provided by the Ministry of Education, Science and Culture of Japan and the Program for Promotion of Fundamental Studies in Health Science of the National Institute of Biomedical Innovation (NIBIO).
###end p 48
###begin p 49
The authors have no conflicting financial interests.
###end p 49

